Latest Ratios: P/E Ratio 14.0x · EV/EBITDA 7.4x · ROE 8.5%. (2016–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.1B | $1.2B | $2.3B | — | — | — | — | — |
| Enterprise Value | $3.6B | $2.8B | $4.0B | — | — | — | — | — |
| P/E Ratio → | 13.95 | 9.20 | 10.81 | — | — | — | — | — |
| P/S Ratio | 0.32 | 0.20 | 0.38 | — | — | — | — | — |
| P/B Ratio | 1.21 | 0.74 | 1.49 | — | — | — | — | — |
| P/FCF | 7.35 | 4.83 | 17.78 | — | — | — | — | — |
| P/OCF | 4.39 | 2.65 | 7.20 | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.44 | 0.67 | — | — | — | — | — |
| EV / EBITDA | 7.38 | 5.83 | 7.23 | — | — | — | — | — |
| EV / EBIT | 11.12 | 8.21 | 9.31 | — | — | — | — | — |
| EV / FCF | — | 10.84 | 31.31 | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 97.5% | 97.5% | 82.7% | 97.4% | 81.4% | 100.0% | 100.0% | 100.0% |
| Operating Margin | 5.1% | 5.1% | 6.8% | 4.2% | 4.2% | 3.6% | 4.1% | 4.0% |
| Net Profit Margin | 2.1% | 2.1% | 3.5% | 0.9% | 3.7% | -3.4% | -1.2% | 0.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|
| ROE | 8.5% | 8.5% | 16.2% | 4.7% | 21.4% | -19.4% | -6.2% | 3.7% |
| ROA | 2.7% | 2.7% | 4.2% | 1.0% | 5.0% | -5.6% | -2.1% | 1.3% |
| ROIC | 7.5% | 7.5% | 9.7% | 5.7% | 6.6% | 6.3% | 8.4% | 11.7% |
| ROCE | 7.9% | 7.9% | 10.0% | 5.6% | 7.0% | 7.5% | 9.3% | 11.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.34 | 1.34 | 1.50 | 2.21 | 2.27 | 1.77 | 1.25 | 0.61 |
| Debt / EBITDA | 4.71 | 4.71 | 4.13 | 6.47 | 6.72 | 4.30 | 4.12 | 1.54 |
| Net Debt / Equity | — | 0.92 | 1.13 | 1.81 | 1.84 | 1.69 | 1.16 | 0.37 |
| Net Debt / EBITDA | 3.23 | 3.23 | 3.13 | 5.29 | 5.44 | 4.10 | 3.81 | 0.95 |
| Debt / FCF | — | 6.01 | 13.53 | 23.24 | — | — | — | 40.82 |
| Interest Coverage | 6.19 | 6.19 | 6.54 | 3.20 | 4.80 | 0.94 | 1.72 | 2.65 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.97 | 1.97 | 1.94 | 1.63 | 1.74 | 1.38 | 1.45 | 1.44 |
| Quick Ratio | 1.85 | 1.85 | 1.82 | 1.52 | 1.61 | 1.24 | 1.29 | 1.29 |
| Cash Ratio | 0.68 | 0.68 | 0.59 | 0.44 | 0.56 | 0.10 | 0.14 | 0.28 |
| Asset Turnover | — | 1.20 | 1.20 | 1.06 | 1.06 | 1.52 | 1.26 | 1.94 |
| Inventory Turnover | 1.31 | 1.31 | 8.98 | 1.34 | 8.91 | — | — | — |
| Days Sales Outstanding | — | 39.60 | 45.46 | 53.02 | 43.54 | 46.40 | 55.18 | 45.26 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | 92.5% | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 7.2% | 10.9% | 9.3% | — | — | — | — | — |
| FCF Yield | 13.6% | 20.7% | 5.6% | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Shares Outstanding | — | $141M | $133M | $143M | $143M | $141M | $141M | $141M |
Includes 30+ ratios · 7 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ARDT stock.
Ardent Health Inc.'s current P/E ratio is 14.0x. The historical average is 10.0x. This places it at the 100th percentile of its historical range.
Ardent Health Inc.'s current EV/EBITDA is 7.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 6.5x.
Ardent Health Inc.'s return on equity (ROE) is 8.5%. The historical average is 4.1%.
Based on historical data, Ardent Health Inc. is trading at a P/E of 14.0x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Ardent Health Inc. has 97.5% gross margin and 5.1% operating margin.
Ardent Health Inc.'s Debt/EBITDA ratio is 4.7x, indicating high leverage. A ratio above 4x may signal elevated financial risk.
Key Metrics
Top Statement Risk
Thin margins amid leverage
Metrics are mathematically derived from official filings.
Discount Multiples Price Limited Earnings Growth
Based on the supplied multiples, ARDT trades at 17.63 trailing P/E and 8.48 EV/EBITDA, a modest premium to CHS-style distressed peers but a discount to HCA's 16.22 P/E and 10.04 EV/EBITDA, suggesting the market prices steady rather than accelerating earnings.
The forward P/E of 19.29 sits above the trailing figure, which implies consensus expects earnings to be lower or flat, not expanding, over the next year. Relative to HCA, the lower EV/EBITDA is consistent with a smaller scale and thinner operating margin of 5.15%, though it should not be read as a clean value signal given the quarterly EPS misses. The P/S of 0.40 and P/FCF of 9.29 look inexpensive, but these multiples rest on free cash flow that the quarterly series shows to be volatile and working-capital dependent.
Gross Margin Reflects Classification, Not Pricing Power
ARDT's reported gross margin swung from roughly 83% in 2025 to 15.9% in 2026Q3, while its net margin of 2.1% and operating margin of 5.1% indicate that true earning power sits well below headline levels.
The collapse in gross margin across quarters appears driven by changes in how clinical labor and supply costs are classified rather than by a shift in pricing, so gross margin is not a reliable basis for comparison here. Operating margin of 5.1% and net margin of 2.1% are the more informative measures, and both sit below HCA's 9.0% net margin and UHS's 8.6%. The gap to peers suggests limited room to absorb further wage inflation or reductions in supplemental government payments.
Returns Decaying Toward Cost of Capital
Based on reported figures, ARDT's ROIC has moved within a 1% to 3% band in recent quarters, and its ROE of 2.5% in 2026Q3 compares with 19.3% for UHS and 32.1% for Tenet, indicating weak capital compounding.
The ROIC trajectory from 8.0% in 2024Q4 to 2.2% in 2026Q3 suggests returns on invested capital have decayed as margins compressed, and the rising equity base has diluted ROE further. Compared with UHS at 12.3% ROIC and HCA at 19.9%, ARDT's returns look structurally lower rather than temporarily depressed. Investors should monitor whether margin recovery can lift ROIC back above the sector range.
Deleveraging Through Equity Rebuild, Not Debt Paydown
According to the reported balance sheet, debt-to-equity fell from 1.93 to 1.27 over eight quarters while total debt held near $2.3B, and debt-to-EBITDA of 16.61 in 2026Q3 remains elevated.
The improvement in leverage ratios reflects equity expansion rather than debt reduction, which means the absolute debt burden is unchanged against a thin 5.15% operating margin. Interest coverage of 6.29 in 2026Q3 is adequate but volatile, having ranged from 1.18 to 11.65 across the period, which suggests debt service comfort depends heavily on the quarter. Refinancing and covenant sensitivity warrant monitoring given the flat debt level.
Liquidity Holds Steady Under Current Ratios
Based on ARDT's reported figures, the current ratio of 2.13 and quick ratio of 2.03 in 2026Q3 indicate short-term obligations are comfortably covered, with cash rising to $766.2M over the period.
Because inventory days are low at 8 and the quick ratio nearly matches the current ratio, liquidity does not depend on inventory conversion. The strengthening cash buffer suggests near-term solvency is not the primary concern. Under severe stress, however, the more relevant constraint is the reliance on working-capital inflows to support free cash flow rather than the current ratio itself.
Misapplied Gross Margin Obscures True Earnings
The gross margin is the ratio most commonly misapplied to ARDT, as its swing from 83% to 15.9% reflects cost reclassification rather than economics, and operating margin of 5.1% better reflects earning power.
Applying gross margin comparisons against non-healthcare industries or against peers reporting clinical labor differently would produce misleading conclusions about pricing power. Analysts should normalize by reclassifying clinical labor into cost of sales, then evaluate operating margin, EBITDA conversion, and SWB expense trends. Investors should monitor whether the ratio gap to HCA and UHS narrows once normalized.